Hemogenyx Pharmaceuticals Share Discussion Threads

[phil1969] 16/4/2020 14:05

Looks like hype over the Lancet article is over. Should be able to dip in at 1.50 towards close or tomorrow.

[lionheart69uk1] 16/4/2020 13:10

You certainly do like the sound of your own voice, purple. As for your query, Phil...if you wait for the news, the share price will have already rocketed.

[phil1969] 16/4/2020 13:07

Possible reason for rise. From earlier today. https://twitter.com/hemogenyx/status/1250727344551182336?s=21A follow up RNS and such a low mcap could see this multi bag overnight. Do I get in now or wait for the news??

[purple11] 16/4/2020 12:12

just correcting back up like a lot of stocks after the crash.

just need some news now.

[purple11] 16/4/2020 11:52

still below the recent placing price.

[purple11] 16/4/2020 11:48

250k at 1.79

news due?

[purple11] 16/4/2020 11:47

200kbuy at 1.75 full ask....

[purple11] 16/4/2020 11:44

lets hope it can sustain some decent rises now.looking strong atm gl

[tullynessle] 16/4/2020 10:38

Re Post 1489

Astra Zeneca are mentioned in The Pharma Letter dated yesterday (April 15, 2020). I do not subscribe so cannot confirm for sure, if the entry below refers to the same story.



The Pharma Letter

Another blood cancer drug shows promise for COVID-19
15-04-2020

As global COVID-19 research continues apace, British drugmaker AstraZeneca has entered the fray with…..

[tullynessle] 16/4/2020 10:31

Well worth reading - the reference to "immunised humanised mice" at the Extract below, may be of interest; especially if a "need" for such an asset is emanating from similar research currently being undertaken throughout the global pharmaceutical industry.


Extract:

"Its scientists are exploring three potential sources for antibodies against the virus that causes Covid-19, known as SARS CoV-2 – patients who have recovered from the disease, immunised humanised mice and laboratory techniques such as phage display."




Cambridge Independent

AstraZeneca targets clinical tests of new Covid-19 antibody treatments in ‘three to five months’
Published: 00:01, 11 April 2020

AstraZeneca is aiming to carry out clinical evaluation of new Covid-19 treatments in three to five months.

The biopharmaceutical company, headquartered in Cambridge, has confirmed it is using a variety of techniques to develop monoclonal antibodies and is teaming up with government agencies and academia to accelerate the work.

Its scientists are exploring three potential sources for antibodies against the virus that causes Covid-19, known as SARS CoV-2 – patients who have recovered from the disease, immunised humanised mice and laboratory techniques such as phage display.

AstraZeneca said it has more than 50 virology, protein engineering, clinical and bioprocess experts across biopharmaceuticals R&D and operations working on the drive to find novel antibodies that can bind to the virus and neutralise it.

Article continues.......

[purple11] 16/4/2020 09:35

same old problem. daytraders

[orchestralis] 16/4/2020 09:04

Hello hello

[purple11] 16/4/2020 08:40

full ask beingpaid.v cheap down here

[purple11] 16/4/2020 08:25

they are working on a "key"for their car t.we may hear something on that.

[scaramouche1941] 15/4/2020 15:58

What are we waiting for?

[on target] 15/4/2020 15:28

What makes you say that?

[clever_trevor6] 15/4/2020 14:58

Hold on tight lads and lasses

Not much longer to wait...

[purple11] 14/4/2020 09:10

hopefully recover to the 1.80 placing price.dont see why not.gl

[purple11] 13/4/2020 20:48

im doing the best I can.